Hepatitis C
EASL 2013: 12 Weeks of Telaprevir Triple Therapy Adequate for Some Hep C Patients
- Details
- Category: HCV Treatment
- Published on Thursday, 13 June 2013 00:00
Nearly 90% of genotype 1 chronic hepatitis C patients with favorable response factors including the IL28B CC gene variant achieved a cure with just 12 weeks of telaprevir (Incicek or Incivo) plus pegylated interferon/ribavirin, rising to 97% for those treated for 24 weeks, researchers reported at the recent EASL International Liver Congress (EASL 2013) in Amsterdam.
Gilead: Sofosbuvir for Hepatitis C Granted FDA Priority Review
- Details
- Category: HCV Treatment
- Published on Thursday, 13 June 2013 00:00
Gilead's investigational nucleotide hepatitis C virus (HCV) polymerase inhibitor sofosbuvir (formerly GS-7977) has been given priority review status by the U.S. Food and Drug Administration, with a target date in early December, the company announced last week.
DDW 2013: Drug Interactions May Compromise Response to Boceprevir and Telaprevir
- Details
- Category: HCV Treatment
- Published on Thursday, 30 May 2013 00:00
Concurrent use of drugs that alter concentrations of boceprevir (Victrelis) or telaprevir (Incivek or Incivo) in the body may contribute to poor response to interferon-based triple therapy for chronic hepatitis C, according to study findings presented at the Digestive Disease Week meeting (DDW 2013) last week in Orlando.
Antiretroviral PrEP Prevents HIV Transmission among Injection Drug Users
- Details
- Category: Injection Drug Use
- Published on Thursday, 13 June 2013 00:00
Pre-exposure prophylaxis (PrEP) using daily oral tenofovir (Viread) reduced the risk of HIV acquisition among injection drug users in Thailand by half, according to findings from the Bangkok Tenofovir Study, published in the June 13, 2013, advance online edition of The Lancet. These findings led the CDC to recommend that PrEP be "considered as one of several prevention options for persons at very high risk for HIV acquisition" through injection drug use.
DDW 2013: Interferon-free Simeprevir + Sofosbuvir Suppresses Hepatitis C with or without Ribavirin
- Details
- Category: HCV Treatment
- Published on Thursday, 30 May 2013 00:00
An all-oral regimen consisting of simeprevir (formerly TMC435) plus sofosbuvir, (formerly GS-7977), with or without ribavirin, produced an 8-week post-treatment cure for most prior null responders with genotype 1 hepatitis C in the COSMOS trial, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last week in Orlando.
War on Drugs Is Major Driver of Global Hepatitis C Epidemic
- Details
- Category: Injection Drug Use
- Published on Thursday, 06 June 2013 00:00
The so-called "war on drugs" plays a major role is sustaining hepatitis C epidemics worldwide, including in hard-hit Russia and Eastern Europe, according to the latest report from the Global Commission on Drug Policy. Drug prohibition drives drug users underground and blocks harm reduction efforts such as needle exchange programs. "The war on drugs is a war on common sense," said Commissioner Ruth Dreifuss.
EASL 2013: HIV/HCV Coinfected Patients More Likely to Develop Cirrhosis, but Treatment Lowers Risk
- Details
- Category: HCV Disease Progression
- Published on Thursday, 30 May 2013 00:00
Sustained response to hepatitis C treatment leads to slow regression of liver fibrosis in people with HIV/HCV coinfection, but they remain at elevated risk for liver cirrhosis compared to those without HCV, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
DDW 2013: Prior Non-responders Can Achieve Good SVR Rates with Boceprevir Triple Therapy
- Details
- Category: HCV Treatment
- Published on Thursday, 06 June 2013 00:00
People previously treated with interferon-based therapy can achieve good results when retreated with boceprevir (Victrelis) triple therapy, according to final results from the PROVIDE study presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando. Prior relapsers had the best response, but even 41% of prior null responders achieved a cure.
DDW 2013: Advanced Fibrosis Does Not Affect Response to Faldaprevir All-oral Regimen
- Details
- Category: HCV Treatment
- Published on Wednesday, 22 May 2013 00:00
An interferon-free combination of faldaprevir, BI 207127, and ribavirin produced high and similar sustained response rates for treatment-naive genotype 1b hepatitis C patients with either absent-to-moderate liver fibrosis or advanced fibrosis/cirrhosis, according to a presentation at the Digestive Disease Week conference (DDW 2013) this week in Orlando.
More Articles...
- DDW 2013: Viral Breakthrough May Occur during Interferon/Ribavirin 'Tail' of HCV Triple Therapy
- DDW 2013: Does Treating Herpes Help Suppress Hepatitis C Virus?
- EASL 2013: Probiotics May Help Manage Hepatic Encephalopathy in Patients with Cirrhosis
- DDW 2013: Simeprevir Boosts Response to Interferon-based Therapy for Prior Relapsers
- Sunday is Hepatitis Testing Day -- All Baby Boomers Should Get Hep C Test
Web Design and Development by